Compound Yanzhang Capsule Has Synergistic And Attenuated Effects On Sarcoma And Its Main Components Have Inhibitory Effects On The Proliferation Of Liver Cancer Cells

Objective To observe anti-tumor effect of Fufang Yanzhang capsule and explore its possible mechanism.Methods The S180 mouse sarcoma models were established,with cyclophosphamide(CTX)as positive control,to observe the influence of the tumor-burdened tumor growth conditions and general conditions,to observe the changes in peripheral white blood cells,tumor inhibiting rate and indexes the spleen and thymus in tumor-bearing mice after oral gavage of Fufang Yanzhang capsule,and to observe the tumor pathological changes.Results Fufang Yanzhang capsule had no obvious effect on the tumor-burdened tumor growth conditions and general conditions,It also no obvious the sarcoma S180 pathological changes.Fufang Yanzhang capsule could antagonize the reduction of white blood cell counts caused by chemotherapy of CTX in S180 tumor-bearing mice(P<0.05).But it had no obvious effect on the drop of spleen and thymus indexes.It also no obvious inhibitory effect on S180 sarcoma in mouse.Conclusion Fufang Yanzhang capsule do not show anti-tumor effect on the S180 mouse sarcoma models lavaged the doses range of 1.5 g/kg?6 g/kg.It can antagonize cyclophosphamide caused WBC decline.It also can improve the number of peripheral blood leukocyte of model mice.Abstract Objective To explore the effect of dehydrocavidine on inhibiting proliferation of liver cancer HepG2 cells and QGY-7703 cells.Methods Cancer cell lines were cultured to exponential phase and divided into groups in which dehydrocavidine(final concentration:25?50?100?200?400?g/mh)and cisplatin(final concentration:2?4?8?16?32?g/mL)of different concentration were added,with the untreated group as negative control.The inhibitory effect of dehydrocavidine and cisplatin on cells were measured by MTT assay,and the morphological changes of cells were also observed under optical microscope.Results MTT assay showed that dehydrocavidine and cisplatin could inhibit the proliferation of HepG2 cells and QGY-7703 cells in dose-dependent manner.Conclusion Dehydrocavidine used on two cell lines HepG2 and QGY-7703,it's IC50 concentration is both high than 50 ?g/mL(the IC50 of HepG2 at 24h?48h?72h are 416.52±98.53?g/mL?159.67±24.14?g/mL?145.03±11.51?g/mL,and of QGY-7703 at 24h?48h?72h are 400.22±97.02?g/ML?187.98±103.57?gg/mL?135.14±17.77?g/mL)(refer to "research methods in pharmacology of Chinese material medica").thus cisplatin as positive control IC50 is lower than 10 ?g/mL(the IC50 of HepG2 at 24h?48h?72h are 11.94±1.45?g/mL?4.31±0.32?g/mL?3.81±0.87?g/mL,and of QGY-7703 at 24h?48h?72h are 9.56±0.41?g/mL?4.50±0.28?g/mL?3.38±0.15?g/mL).It means that dehydrocavidine hardly inhibit the proliferation of the two cells.